Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees. The grants total 104,400 shares of common stock with an exercise price of $5.29 per share, matching the company's last reported sale price on May 1, 2025.

The stock options, approved under Olema's 2022 Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and the remaining portion vesting in 36 monthly installments. The options have a 10-year term and are contingent on continuous employment.

SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares of the Company's common stock, effective as of May 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $5.29 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on May 1, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

What stock options did Olema Pharmaceuticals (OLMA) grant to new employees in May 2025?

Olema granted stock options for 104,400 shares to four new employees at an exercise price of $5.29 per share, with a 10-year term and four-year vesting schedule.

How does the vesting schedule work for OLMA's May 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting in 36 equal monthly installments over the following three years.

What is the exercise price for Olema's May 2025 inducement stock options?

The exercise price is $5.29 per share, equal to OLMA's last reported sale price on Nasdaq on May 1, 2025.

Under which plan were OLMA's May 2025 employee stock options granted?

The stock options were granted under Olema's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).